Explore the future of biomedical research and drug development in our informative webinar, where we explore the exciting world of CRISPR-Cas9 gene editing and human induced pluripotent stem cell (iPSC)-derived cells. Learn about the gene-editing capabilities of CRISPR-Cas9 and its applications in biomedical R&D, and how this technology is unlocking new therapeutic possibilities. Learn about iPSCs, the cells that have the potential to generate all adult cell types, and their promising applications in medicine. Discover the synergy of iPSC-derived cells and CRISPR as we explore how we can combine these technologies to model disease mechanisms, identify drug targets, and study therapeutic responses. Plus, gain valuable insights into bit.bio discovery’s technology platform and its capabilities in functional genomic screening using iPSCs and CRISPR for efficient drug target identification and validation.
Sejla received her training as a stem cell biologist in the laboratory of Sasha Mendjan at the Institute of Molecular Biotechnology (IMBA) in Vienna, Austria. She embarked on her biotech career at Signalomics and Haplogen, where she made valuable contributions to the development of an antiviral drug candidate. In 2019, she assumed the role of Project Lead at Myllia Biotechnology (formerly Aelian Biotechnology), and subsequently progressed to Team Lead. Sejla’s journey continued in 2020 when she joined bit.bio discovery as the R&D Team Lead, later advancing to the position of Director of R&D and now Vice President of R&D. She strongly believes in the power of teamwork and collaboration, recognizing the importance of fostering an inclusive and innovative environment that empowers individuals to thrive and make meaningful contributions.